Shares of Hologic (HOLX) Sees Large Inflow of Net Money Flow

Hologic (HOLX): $1.24 million was the positive money flow into the stock on Friday and the up/down ratio of ticks was also in favor of the bulls at 1.49. The value of trades done on upticks was $3.77 million, whereas, trades done on downticks were valued at $2.52 million. Money flows are calculated as the dollar value of composite uptick trades minus the dollar value of downtick trades. large traders, also sometimes called as the smart money, block traded $1.34 million worth stocks on upticks, which is a bullish indication. The money flow in block trades was $1.34 million. Hologic (HOLX) fell $0.07 traded at $38.4, a change of -0.17% over the previous day. The stock is -1.04% for the week.


The company Insiders own 0.84% of Hologic shares according to the proxy statements. Institutional Investors own 94.98% of Hologic shares.

In a related news,The director of Hologic Inc, Crawford Sally sold 16,071 shares at $37 on July 21, 2016. The Insider selling transaction had a total value worth of $594,627. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Hologic (NASDAQ:HOLX): The stock opened at $38.66 and touched an intraday high of $38.77 on Friday. During the day, the stock corrected to an intraday low of $38.365, however, the bulls stepped in and pushed the price higher to close in the green at $38.51 with a gain of 0.13% for the day. The total traded volume for the day was 1,296,867. The stock had closed at $38.46 in the previous trading session.

Hologic (HOLX) : During the past 4 weeks, traders have been relatively bearish on Hologic (HOLX), hence the stock is down -1.05% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.25% relative to the S&P 500. The 4-week change in the price of the stock is -1.18% and the stock has fallen -0.75% in the past 1 week.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.